Physician profile

Daniel J Tarditi

Cardiovascular Disease · Haddon Heights, NJ

NPI 1386672467

$12,308.37

in general payments reported to CMS, 2019-2025

39 companies · $1,174 in 2025

The $1,174 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

See the full distribution for Cardiovascular Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,484.18

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $4,435.48 2019-2025 Aveir, Thoratec Heartmate 3 Lvas Implant Kit, Hi-Torque Advance
Novartis Pharmaceuticals Corporation $844.39 2019-2025
Impulse Dynamics (USA) INC. $705.63 2021-2025 Optimizer, Optimizer
Amgen INC. $690.36 2019-2025 Repatha, Repatha
Janssen Pharmaceuticals, INC $623.72 2019-2024 Xarelto
Boehringer Ingelheim Pharmaceuticals, INC. $604.43 2019-2025 Jardiance
Astrazeneca Pharmaceuticals LP $577.67 2019-2024 Wainua
Pfizer INC. $575.28 2019-2025
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $555.44 2019-2025 Lifevest
Boston Scientific Corporation $472.76 2019-2024 Watchman Flx
Merck Sharp & Dohme LLC $355.14 2022-2025 Verquvo
E.R. Squibb & Sons, L.L.C. $296.76 2019-2025 Camzyos, Eliquis
Amarin Pharma, INC. $273.81 2019-2021
Bayer Healthcare Pharmaceuticals INC. $207.67 2022-2025
Esperion Therapeutics, INC. $143.34 2020-2024 Nexletol
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Medtronic, INC. $139.65 2024 Pipeline, Abre
W. L. Gore & Associates, INC. $134.85 2019-2022
Cvrx, INC. $84.15 2024 Barostim Neo System
Regeneron Healthcare Solutions, INC. $72.72 2019-2024 Evkeeza
Sanofi-Aventis U.S. LLC $63.16 2019-2020
Scpharmaceuticals INC. $49.47 2024
Edwards Lifesciences Corporation $49.00 2019
Novo Nordisk INC $46.16 2024-2025 Wegovy
Astellas Pharma US INC $39.85 2019
Kiniksa Pharmaceuticals, LTD. $28.29 2022-2023 Arcalyst
Inspire Medical Systems, INC. $27.40 2024 Inspire
Heartflow, INC. $23.07 2025
Acarix USA INC. $18.90 2024 Cadscor System
Akcea Therapeutics, INC. $18.86 2019
Glaxosmithkline, LLC. $17.96 2025 Shingrix, Arexvy
Vifor Pharma, INC. $17.56 2019
Regeneron Pharmaceuticals, INC. $16.80 2019
Bridgebio Pharma, INC. $16.35 2025 Attruby
Actelion Pharmaceuticals US, INC. $14.92 2022
Azurity Pharmaceuticals, INC. $14.15 2024 Edarbi
Arbor Pharmaceuticals, INC. $13.93 2019
Kiniksa Pharmaceuticals International, Plc $13.91 2024 Arcalyst
Otsuka America Pharmaceutical, INC. $13.89 2019
Lundbeck LLC $11.49 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel J Tarditi

$12,308.37

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $1,174 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/153231/daniel-j-tarditi

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.